Found: 64
Select item for more details and to access through your institution.
A single case of Rosai-Dorfman disease marked by pathologic fractures, kidney failure, and liver cirrhosis treated with single-agent cladribine.
- Published in:
- Frontiers in Oncology, 2014, v. 4, p. 1, doi. 10.3389/fonc.2014.00297
- By:
- Publication type:
- Article
Therapy of newly diagnosed follicular lymphoma.
- Published in:
- Frontiers in Oncology, 2012, v. 2, p. 1, doi. 10.3389/fonc.2012.00188
- By:
- Publication type:
- Article
Therapy of Newly Diagnosed Follicular Lymphoma.
- Published in:
- Frontiers in Oncology, 2012, v. 2, p. 1, doi. 10.3389/fonc.2012.00188
- By:
- Publication type:
- Article
Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell Lymphoma.
- Published in:
- Current Oncology Reports, 2023, v. 25, n. 11, p. 1387, doi. 10.1007/s11912-023-01466-6
- By:
- Publication type:
- Article
Real‐world analysis of safety and efficacy of CAR T‐cell therapy in lymphoma patients with decreased kidney function.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 1, p. e11, doi. 10.1111/bjh.19152
- By:
- Publication type:
- Article
Outcomes and management of patients with mantle cell lymphoma after progression on brexucabtagene autoleucel therapy.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 2, p. e38, doi. 10.1111/bjh.17197
- By:
- Publication type:
- Article
Lenalidomide plus rituximab (R<sup>2</sup>) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 5, p. 874, doi. 10.1111/bjh.15843
- By:
- Publication type:
- Article
Stage I Non‐Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement.
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 2, p. 334, doi. 10.1111/bjh.15444
- By:
- Publication type:
- Article
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
- Published in:
- 2018
- By:
- Publication type:
- Letter to the Editor
Four‐year follow‐up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL).
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 3, p. 404, doi. 10.1111/bjh.15411
- By:
- Publication type:
- Article
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.
- Published in:
- British Journal of Haematology, 2018, v. 181, n. 2, p. 264, doi. 10.1111/bjh.14544
- By:
- Publication type:
- Article
Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 5, p. 851, doi. 10.1111/bjh.14267
- By:
- Publication type:
- Article
Dose adjusted- EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 3, p. 503, doi. 10.1111/bjh.14226
- By:
- Publication type:
- Article
High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R- FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.
- Published in:
- British Journal of Haematology, 2017, v. 177, n. 2, p. 263, doi. 10.1111/bjh.14541
- By:
- Publication type:
- Article
The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.
- Published in:
- British Journal of Haematology, 2017, v. 176, n. 5, p. 750, doi. 10.1111/bjh.14477
- By:
- Publication type:
- Article
Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 2, p. 290, doi. 10.1111/bjh.14237
- By:
- Publication type:
- Article
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
- Published in:
- British Journal of Haematology, 2016, v. 172, n. 1, p. 80, doi. 10.1111/bjh.13796
- By:
- Publication type:
- Article
A clinician's guide to double hit lymphomas.
- Published in:
- British Journal of Haematology, 2015, v. 168, n. 6, p. 784, doi. 10.1111/bjh.13276
- By:
- Publication type:
- Article
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non- Hodgkin lymphoma.
- Published in:
- British Journal of Haematology, 2014, v. 167, n. 2, p. 177, doi. 10.1111/bjh.13014
- By:
- Publication type:
- Article
Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma.
- Published in:
- British Journal of Haematology, 2014, v. 166, n. 1, p. 1, doi. 10.1111/bjh.13014
- By:
- Publication type:
- Article
Could treatment with R- HCVAD/R- MA as compared to R- CHOP truly result in improved outcomes for patients with high-risk diffuse large B cell lymphoma? - Response to Landsburg et al.
- Published in:
- British Journal of Haematology, 2014, v. 165, n. 1, p. 146, doi. 10.1111/bjh.12704
- By:
- Publication type:
- Article
Prospective phase II study of rituximab with alternating cycles of hyper- CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma.
- Published in:
- British Journal of Haematology, 2013, v. 163, n. 5, p. 611, doi. 10.1111/bjh.12585
- By:
- Publication type:
- Article
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 5, p. 880, doi. 10.1002/ajh.27283
- By:
- Publication type:
- Article
Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA‐1, and TRANSCEND trials.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 10, p. 1295, doi. 10.1002/ajh.26301
- By:
- Publication type:
- Article
Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?
- Published in:
- 2019
- By:
- Publication type:
- journal article
Accelerated therapeutic progress in diffuse large B cell lymphoma.
- Published in:
- Annals of Hematology, 2014, v. 93, n. 4, p. 541, doi. 10.1007/s00277-013-1979-7
- By:
- Publication type:
- Article
ICU Resource Use in Critically III Patients following Chimeric Antigen Receptor T-Cell Therapy.
- Published in:
- 2020
- By:
- Publication type:
- Letter
ICU Resource Use in Critically Ill Patients following Chimeric Antigen Receptor T-Cell Therapy.
- Published in:
- American Journal of Respiratory & Critical Care Medicine, 2020, v. 202, n. 8, p. 1184, doi. 10.1164/rccm.202002-0286le
- By:
- Publication type:
- Article
The Effect of Zoledronic Acid on the Prevention of Bone Loss in Lymphoma Patients Receiving First-line Therapy.
- Published in:
- Clinical Lymphoma & Myeloma, 2009, v. 9, n. 6, p. E30, doi. 10.3816/CLM.2009.n.092
- By:
- Publication type:
- Article
A rare case of methotrexate and primaquine co‐administration in a mantle cell lymphoma patient.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2019, v. 44, n. 5, p. 800, doi. 10.1111/jcpt.12849
- By:
- Publication type:
- Article
Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 2, p. 99, doi. 10.1016/j.clml.2012.11.002
- By:
- Publication type:
- Article
Bone Loss in Lymphoma Patients Prior to Receiving Front-line Therapy.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2010, v. 10, n. 3, p. E32, doi. 10.3816/CLML.2010.n.042
- By:
- Publication type:
- Article
Steroid-Refractory Acute GVHD: Predictors and Outcomes.
- Published in:
- 2011
- By:
- Publication type:
- Journal Article
Steroid-Refractory Acute GVHD: Predictors and Outcomes.
- Published in:
- Advances in Hematology, 2011, v. 2011, p. 1, doi. 10.1155/2011/601953
- By:
- Publication type:
- Article
Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. 504, doi. 10.1016/j.clml.2021.12.014
- By:
- Publication type:
- Article
Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 1, p. 52, doi. 10.1016/j.clml.2021.07.020
- By:
- Publication type:
- Article
Innovative Approaches in Untreated DLBCL.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S183, doi. 10.1016/S2152-2650(21)01259-3
- By:
- Publication type:
- Article
Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Rosai-Dorfman Disease: The MD Anderson Cancer Center Experience.
- Published in:
- 2019
- By:
- Publication type:
- journal article
BELINDA: A Phase 3 Study Evaluating the Safety and Efficacy of Tisagenlecleucel versus Standard of Care in Adult Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S270, doi. 10.1016/j.clml.2019.07.197
- By:
- Publication type:
- Article
Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S251, doi. 10.1016/j.clml.2019.07.158
- By:
- Publication type:
- Article
Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)—An Interim Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S373, doi. 10.1016/j.clml.2017.07.213
- By:
- Publication type:
- Article
What to Do With Success? The Optimist's Creed in Relapsed Hodgkin Lymphoma.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Deeper Insights Into Vanishing Bile Duct Syndrome in Lymphoma: A Perplexing Entity.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 6, p. N.PAG, doi. 10.1038/s41408-019-0208-6
- By:
- Publication type:
- Article